ACUT (Accustem Sciences) Total Tax Payable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Total Tax Payable?

Accustem Sciences's Total Tax Payable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accustem Sciences Total Tax Payable Historical Data

The historical data trend for Accustem Sciences's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Total Tax Payable Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Dec24

Total Tax Payable

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial							-	-	-	-	-

Accustem Sciences Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Accustem Sciences Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001

Website

https://www.accustem.com

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.